Dilated cardiomyopathy (DCM) remains a major cause of heart failure and carries a poor prognosis despite important advances in recent years. Better disease characterization using novel molecular techniques is needed to refine its progression. This study explored the proteomic signature of plasma-derived extracellular vesicles (EVs) obtained from DCM patients and healthy controls using size-exclusion chromatography (SEC). EV-enriched fractions were analyzed by liquid chromatography-mass spectrometry (LC-MS/MS). Raw data obtained from LC-MS/MS were analyzed against the Uniprot human database using MaxQuant software. Additional analyses using Perseus software were based on the Intensity-Based Absolute Quantification (iBAQ) values from MaxQuant analyses. A total of 90.07 ± 21 proteins (227 different proteins) in the DCM group and 96.52 ± 17.91 proteins (183 different proteins) in the control group were identified. A total of 176 proteins (74.6%) were shared by controls and DCM patients, whereas 51 proteins were exclusive for the DCM group and 7 proteins were exclusive for the control group. Fibrinogen (α, β and γ chain), serotransferrin, α-1-antitrypsin, and a variety of apolipoprotein family members (C-I, C-III, D, H or β-2-glycoprotein, and J or clusterin) were clustered in SEC-EVs derived from DCM patients relative to controls (p < 0.05). Regarding Gene Ontology analysis, response to stress and protein activation-related proteins were enriched in DCM-EVs compared with controls. Thus, the present study reports the distinct proteomic signature of circulating DCM-EVs compared with control-EVs. Furthermore, we confirm that SEC obtains highly purified EV fractions from peripheral blood samples for subsequent use in determining disease-specific proteomic signatures.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $36.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
We specifically acknowledge Dr. Francisco Sánchez-Madrid (Servicio de Inmunología, Hospital Universitario de la Princesa, IIS-IP, UAM; Cell-Cell Communication Laboratory, CNIC) and Dr. María Yáñez-Mó (Unidad de Investigación, Hospital Sta Cristina, IIS-IP; Departamento Biología Molecular/CBM-SO, UAM) for kindly gifting antibodies against CD9, CD63 and CD81. We also thank Beatriz González, Roser Cabanes, Margarita Rodríguez, Carmen Rivas, Nuria Benito and Alba Ros for invaluable work in the Heart Failure Clinic; Eduard Sabido and Eva Borràs from the UPF/CRG Proteomics Unit for proteomic data processing and analysis; and Hernando del Portillo (ICREA Research Professor at ISGLOBAL-IGTP) for access to the NTA instrument.
This work was supported by grants from the Ministerio de Economía, Industria y Competitividad (SAF2014-59892-R), Fundació La MARATÓ de TV3 (201405/10, 201502, 201516), Societat Catalana de Cardiologia, Generalitat de Catalunya (SGR 2014, CERCA Programme) and the Fundació Bancària La Caixa. This work was also funded by the Red de Terapia Celular—TerCel (RD16/0011/0006), CIBER Cardiovascular—(CB16/11/00403), and Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (FIS PI14/01682) as part of the Plan Nacional de I+D+I cofounded by ISCIII-Sudirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER).
About this article
Quantitative proteomics study reveals differential proteomic signature in dilated, restrictive, and hypertrophic cardiomyopathies
Journal of Proteins and Proteomics (2019)